Metastatic cancer is a major cause of morbidity and mortality. Current therapeutic options consist of chemotherapy, radiation or targeted therapies. However, these therapies are often toxic, effective over a small range of cancer types or result in drug resistance. Therefore, a more global, less toxic strategy for the management of metastatic cancer is required. Although most cancers display increased glucose metabolism, glutamine is also a major energy substrate for many cancers. We evaluated the antimetastatic potential of 6-diazo-5-oxo-L-norleucine (DON), a glutamine analog, using the new VM mouse model of systemic metastasis. We found that primary tumor growth was ∼20-fold less in DON-treated mice than in untreated control mice. We also found that DON treatment inhibited metastasis to liver, lung and kidney as detected by bioluminescence imaging and histology. Our findings provide proof of concept that metabolic therapies targeting glutamine metabolism can manage systemic metastatic cancer.
Metastatic cancer is a major cause of morbidity and mortality. Current therapeutic options consist of chemotherapy, pan class="Disease">radiation or targeted therapies. However, these therapies are often toxic, effective over a small range of cancer types or result in drug resistance. Therefore, a more global, less toxic strategy for the management of metastatic cancer is required. Although most cancers display increased glucose metabolism, glutamine is also a major energy substrate for many cancers. We evaluated the antimetastatic potential of 6-diazo-5-oxo-L-norleucine (DON), a glutamine analog, using the new VM mouse model of systemic metastasis. We found that primary tumor growth was ∼20-fold less in DON-treated mice than in untreated control mice. We also found that DON treatment inhibited metastasis to liver, lung and kidney as detected by bioluminescence imaging and histology. Our findings provide proof of concept that metabolic therapies targeting glutamine metabolism can manage systemic metastatic cancer.
Authors: Leanne C Huysentruyt; Purna Mukherjee; Dia Banerjee; Laura M Shelton; Thomas N Seyfried Journal: Int J Cancer Date: 2008-07-01 Impact factor: 7.396
Authors: Colin Selman; Nicola D Kerrison; Anisha Cooray; Matthew D W Piper; Steven J Lingard; Richard H Barton; Eugene F Schuster; Eric Blanc; David Gems; Jeremy K Nicholson; Janet M Thornton; Linda Partridge; Dominic J Withers Journal: Physiol Genomics Date: 2006-08-01 Impact factor: 3.107
Authors: Vera F Monteiro-Cardoso; Amélia M Silva; Maria M Oliveira; Francisco Peixoto; Romeu A Videira Journal: J Bioenerg Biomembr Date: 2014-02 Impact factor: 2.945
Authors: Lukáš Tenora; Jesse Alt; Ranjeet P Dash; Alexandra J Gadiano; Kateřina Novotná; Vijayabhaskar Veeravalli; Jenny Lam; Quinn R Kirkpatrick; Kathryn M Lemberg; Pavel Majer; Rana Rais; Barbara S Slusher Journal: J Med Chem Date: 2019-03-29 Impact factor: 7.446
Authors: Mohamed Hassanein; Matthew R Hight; Jason R Buck; Mohammed N Tantawy; Michael L Nickels; Megan D Hoeksema; Bradford K Harris; Kelli Boyd; Pierre P Massion; H Charles Manning Journal: Mol Imaging Biol Date: 2016-02 Impact factor: 3.488
Authors: Eduard H Panosyan; Yuntao Wang; Peng Xia; Wai-Nang Paul Lee; Youngju Pak; Dan R Laks; Henry J Lin; Theodore B Moore; Timothy F Cloughesy; Harley I Kornblum; Joseph L Lasky Journal: Mol Cancer Res Date: 2014-02-06 Impact factor: 5.852
Authors: Angela Poff; Andrew P Koutnik; Kathleen M Egan; Solmaz Sahebjam; Dominic D'Agostino; Nagi B Kumar Journal: Semin Cancer Biol Date: 2017-12-30 Impact factor: 15.707